epaminurad
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 14, 2023 (NCT05815901)
Timeline
Indications
Studied for
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
SLC22A12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1cc(Br)c(O)c(Br)c1)N1CCOc2ccncc21- Mol. weight
- 414.05 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4640580 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07036458 | Phase 1 | Aug 22, 2025 | JW Pharmaceutical, Quotient |
| NCT06665425 | Phase 1 | Nov 30, 2024 | JW Pharmaceutical, Seoul National University |
| NCT06435442 | Phase 1 | May 31, 2024 | JW Pharmaceutical, Seoul National University |
| NCT05815901 | Phase 3 | Mar 14, 2023 | Inha University, JW Pharmaceutical |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| JW Pharmaceutical | For profit | 4 | 4 | 2 | 2023 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Inha University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Quotient | For profit | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1